CAGNY 2026 A PROVEN GROWTH MODEL, POSITIONED TO REACCELERATE GROWTH February 17, 2026 FORWARD-LOOKING STATEMENTS This presentation and accompanying prepared remarks contain forward-looking statements. All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws. Words, and variations of words, such as "will," "may," "expect," "would," "could," "might," "intend," "plan," "believe," "likely," "estimate," "anticipate," "objective," " ...

Financial Data and Key Metrics Changes - Revenue in Q4 2025 was $474 million, a 19.5% sequential increase driven by elevated sales activity [12] - Gross margin before inventory-related charges was over 19%, with an adjusted gross margin of over 22% [6][13] - Net income for Q4 was $17.3 million, or $0.75 per share, while excluding impairment-related charges, net income was $22.4 million, or $0.97 per share [15] Business Line Data and Key Metrics Changes - The company delivered 1,362 homes in Q4, with 1,301 contributing directly to revenue [5] - The average selling price of homes in Q4 was $364,000, slightly down compared to the previous year [12] - The wholesale business accounted for 12.1% of Q4 closings, generating significant revenue [12] Market Data and Key Metrics Changes - The cancellation rate increased to 43.3%, influenced by affordability pressures and economic uncertainty [9] - The backlog grew 133% to 1,394 homes, with a value exceeding $501 million, up 112% year-over-year [10] - The company ended the year with 144 active communities, averaging 3.1 closings per community per month in Q4 [8] Company Strategy and Development Direction - The company remains focused on managing costs, offering competitive financing options, and delivering affordable homes to first-time buyers [11] - Long-term outlook for the housing market remains positive, driven by supply-demand imbalance and favorable demographic trends [11] - The company plans to continue investing in people, land, and operating platforms to support long-term strategy [11] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the dynamic market environment, with affordability being a primary pressure point [5] - The expectation for 2026 includes closing between 4,600 and 5,400 homes, with stable selling prices [23] - Management indicated that incentives will continue to be utilized to support affordability while maintaining margin discipline [23] Other Important Information - The company ended the year with $1.7 billion of debt outstanding and a net debt to capital ratio of 43.2% [20] - Total liquidity at year-end was $335 million, including over $61 million in cash [20] - The average finished lot cost is approximately $70,000, representing about 21% of the average selling price [18] Q&A Session Summary Question: Drivers of sequential decline in gross margin in Q4 - Management indicated that the decline was due to increased incentives and discounts on aged inventory [26][27] Question: Closings outlook for 2026 - Management expects a similar closings pace in 2026, with wholesale closings projected to be 10%-15% of total closings [29][31] Question: Profitability on wholesale orders - Management stated that gross margins on wholesale sales are lower, but operating margins are similar to retail [36] Question: Community count growth expectations for 2026 - New community openings are expected to be weighted towards the back half of the year [38] Question: Cancellations and reasons for cancellation - The cancellation rate is elevated primarily due to financing challenges faced by buyers [44][45] Question: Mix of first-time versus move-up buyers - The proportion of move-up buyers is increasing due to elevated entry-level price points [50] Question: Current market conditions and discounting - Management noted that affordability pressures remain, with competitors also leaning into incentives [53][54] Question: Year-over-year decline in G&A - Management indicated that G&A run rate for 2026 is expected to be similar to 2025 [56]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $474 million, representing a 19.5% sequential increase driven by elevated sales activity [11] - Gross margin before inventory-related charges was over 19%, with an adjusted gross margin of over 22%, although these were below guidance ranges due to the impact of buydowns and price discounts on older inventory [5][6] - Net income for Q4 was $17.3 million, or $0.75 per share, while excluding impairment-related charges, net income was $22.4 million, or $0.97 per share [14] Business Line Data and Key Metrics Changes - In Q4, 1,362 homes were delivered, with 1,301 contributing directly to reported revenue [4] - The average selling price for Q4 closings was $364,000, slightly down compared to the previous year [11] - The wholesale business accounted for 12.1% of Q4 closings, generating significant revenue [11] Market Data and Key Metrics Changes - The cancellation rate increased to 43.3%, attributed to affordability pressures and economic uncertainty [8] - The backlog grew 133% to 1,394 homes, with a value exceeding $501 million, up 112% year-over-year [9] Company Strategy and Development Direction - The company remains focused on managing costs, offering competitive financing options, and delivering affordable homes to first-time buyers [10] - Long-term outlook for the housing market remains positive, driven by supply-demand imbalance and favorable demographic trends [10] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by affordability and rate volatility but expressed confidence in the company's ability to navigate these issues [4] - For 2026, the company expects to close between 4,600 and 5,400 homes, with stable selling prices and continued use of incentives to support affordability [22][23] Other Important Information - The company ended the year with $1.7 billion of debt and a net debt to capital ratio of 43.2% [19] - Total liquidity at year-end was $335 million, including cash on hand and revolver availability [19] Q&A Session Summary Question: Drivers of sequential decline in gross margin in Q4 - Management indicated that the decline was due to increased incentives and discounts on aged inventory, with expectations for similar conditions in 2026 [26][27] Question: Closings outlook for 2026 - Management confirmed expectations for a similar closings pace in 2026, with wholesale business contributing 10%-15% of total closings [28][30] Question: Profitability on wholesale orders - Management stated that operating margins for wholesale business are similar to retail, but gross margins are lower [35] Question: Community count growth expectations for 2026 - New community openings are expected to be weighted towards the back half of the year, with confidence in achieving the community count guidance [37] Question: Cancellations and buyer financing issues - Management noted that cancellations are primarily due to buyers' ability to secure financing, with customers taking longer to close [43][44] Question: Current market conditions and discounting - Management acknowledged ongoing aggressive discounting in the market, with affordability pressures remaining a significant concern [52] Question: Year-over-year decline in G&A - Management indicated that G&A run rate for 2026 is expected to be similar to 2025, with some fluctuations quarter to quarter [55]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $474 million, representing a 19.5% sequential increase driven by elevated sales activity [10] - Gross margin before inventory-related charges was over 19%, with an adjusted gross margin of over 22%, both below guidance ranges due to the impact of buydowns and price discounts on older inventory [5][11] - Pre-tax net income was $24 million, or 5.1% of revenue, with net income of $17.3 million, or $0.75 per share [13] Business Line Data and Key Metrics Changes - The company delivered 1,362 homes in Q4, with 1,301 contributing to reported revenue [4] - The average selling price for Q4 closings was $364,000, slightly down from the previous year [10] - The wholesale business accounted for 12.1% of Q4 closings, generating significant revenue [10] Market Data and Key Metrics Changes - The cancellation rate increased to 43.3%, attributed to affordability pressures and economic uncertainty [7] - The backlog grew 133% to 1,394 homes, with a value exceeding $501 million, up 112% year-over-year [8] Company Strategy and Development Direction - The company remains focused on managing costs, offering competitive financing options, and delivering affordable homes to first-time buyers [9] - Long-term outlook for the housing market remains positive, driven by supply-demand imbalance and favorable demographic trends [9] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges of affordability and rate volatility but expressed confidence in the company's ability to navigate these issues [4] - For 2026, the company expects to close between 4,600 and 5,400 homes, with stable selling prices and a focus on maintaining margins [21] Other Important Information - The company ended the year with $1.7 billion in debt and a net debt to capital ratio of 43.2% [19] - Total liquidity at year-end was $335 million, including cash on hand and revolver availability [19] Q&A Session Summary Question: What drove the sequential decline in gross margin in Q4? - Management indicated that the decline was due to increased incentives and discounts on aged inventory, along with competitive pricing pressures [26] Question: What is the outlook for closings in 2026? - Management confirmed expectations for a similar closings pace in 2026, with wholesale closings projected to be 10%-15% of total closings [28] Question: How will profitability be affected by the 480 orders in the wholesale business? - Management stated that while gross margins are lower for wholesale sales, operating margins remain similar to retail [34] Question: What is the current mix of first-time versus move-up buyers? - Management noted an increase in move-up buyers due to elevated entry-level price points, although first-time buyers still dominate [49] Question: What are the current conditions regarding affordability and discounting? - Management acknowledged ongoing affordability challenges and the need for continued incentives to assist buyers [52]

Bayer Update Summary Company Overview - **Company**: Bayer (OTCPK:BAYR.Y) - **Date of Briefing**: February 17, 2026 Key Points Legal Settlements and Litigation - Bayer has reached a settlement agreement regarding glyphosate-related litigation, which is currently pending court approval in Missouri. This agreement is crucial as it addresses a significant number of current and future claims related to Non-Hodgkin Lymphoma (NHL) allegedly caused by Roundup exposure [1][10][12] - The settlement is designed to provide closure for the Roundup litigation and is supported by several leading plaintiff law firms, indicating a fair arrangement for plaintiffs [13][14] - The company has increased its litigation provision from EUR 7.8 billion to EUR 11.8 billion, with approximately EUR 9.6 billion allocated for glyphosate-related claims and EUR 1.9 billion for PCB-related claims [5][27] - Bayer anticipates litigation-related cash outflows of approximately EUR 5 billion in 2026, leading to negative free cash flow for that year [6][28] Supreme Court Involvement - The Supreme Court's decision on the Durnell case is critical as it could impact claims not covered by the settlement and provide clarity on federal preemption regarding crop protection products [2][11] - A favorable ruling could disincentivize opt-outs from the settlement and provide essential regulatory clarity for U.S. farmers [2][11] Financial Implications - Bayer plans to finance the settlement through a secured bank loan facility of $8 billion and will not utilize previously authorized capital increases [7][28] - The company expects annual litigation-related payments to stabilize at approximately EUR 1 billion for five years following 2026, after which payments will significantly decrease [6][28] Future Outlook - Bayer is committed to its mission of "health for all, hunger for none" and aims to focus on its pharmaceutical pipeline and agricultural innovations [18] - The company is preparing to launch new products, including a new herbicide, Icafolin, in Brazil, highlighting the urgency for regulatory clarity in the U.S. [3][8] Additional Considerations - The settlement process includes a robust notice system for class members, allowing them to opt-out if desired. Bayer retains the right to terminate the settlement if opt-outs exceed a certain threshold [15][16] - The settlement is structured to address both current and future claims, reflecting the long latency of NHL, and will run for up to 21 years [14][16] Strategic Focus - Bayer is undergoing a transformation to enhance its operational efficiency and is focused on maintaining a solid investment grade while managing its debt levels [49][75] - The company emphasizes the importance of being the best home for its various business segments, including pharmaceuticals and crop science [48][49] Conclusion - Bayer's recent developments in litigation settlements and strategic focus on innovation and regulatory clarity are pivotal for its future growth and operational stability. The outcomes of the Supreme Court case and the acceptance of the settlement will significantly influence the company's trajectory in the coming years [1][2][18]

Bayer (OTCPK:BAYR.Y) Update / briefing February 17, 2026 12:30 PM ET Company ParticipantsAnja Ettel - News reporterBill Anderson - CEOBill Dodero - Head of Litigation and North America LegalCharles Pitman-King - VPDietrich Knauth - Media RepresentativeJost Reinhard - Head of Investor RelationsSonja Wind - News ReporterWolfgang Nickl - CFOConference Call ParticipantsAlec Ebeling - Equity Research AnalystBert Günther - Equity Research AnalystLaurent Favre - Equity Research AnalystRajesh Kumar - Equity Researc ...

Financial Data and Key Metrics Changes - Total revenue increased by 19% to $3.7 billion in 2025, driven by strong execution across the royalty portfolio and commercialized medicines [25][26] - Operating profit expanded to $1.26 billion, reflecting strong execution and increasing operating leverage as the business scales [26][30] - Sales of proprietary medicines totaled $632 million, up 54% year-over-year, accounting for approximately 28% of total revenue growth [16][25] Business Line Data and Key Metrics Changes - Epkinly achieved $468 million in sales for 2025, representing a 67% year-over-year increase, driven by its dual indication in diffuse large B-cell lymphoma and follicular lymphoma [17][19] - Tivdak generated $164 million in sales, a 26% year-over-year increase, maintaining market leadership in recurrent or metastatic cervical cancer [20][21] Market Data and Key Metrics Changes - Epkinly closed 2025 with regulatory approvals in over 65 countries, nearly all featuring the dual indication [17] - The U.S. market saw increased uptake for Epkinly, particularly in community settings, with a majority of health systems ordering from multiple sites [18] Company Strategy and Development Direction - The company aims to accelerate the development of its late-stage pipeline and maximize the potential of its commercialized medicines, with a focus on sustainable growth into the 2030s [5][6] - The acquisition of Merus is expected to enhance the late-stage portfolio with petosemtamab, providing multiple value-creating catalysts in 2026 and beyond [8][26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to execute on key data readouts in 2026 and subsequent high-impact launches in 2027, emphasizing a disciplined approach to capital allocation [31] - The company anticipates continued momentum in Epkinly and its royalty portfolio, with a revenue growth guidance of 14% for 2026 [27][30] Other Important Information - The company has five combined breakthrough therapy designations for its late-stage programs, which have multi-billion dollar potential [9] - The company is committed to deleveraging, targeting gross leverage below 3x by the end of 2027 [30] Q&A Session Summary Question: Next steps for Epkinly following EPCORE DLBCL-1 study results? - Management confirmed that the study showed positive progression-free survival but missed overall survival, and discussions with regulatory agencies are ongoing regarding the next steps [34][36] Question: Update on outpatient data for Epkinly? - Management indicated that the outpatient study is crucial for modifying the label and facilitating administration in the community [43][46] Question: Expectations for Rina-S pivotal phase two readout? - Management stated that the study is designed to support accelerated approval based on overall response rate and duration of response [51][54] Question: Expectations for EPCORE DLBCL 4 trial? - Management expressed optimism that the trial will lead to registration in second-line and third-line settings, differentiating it from other studies [58][60] Question: Thoughts on pembro approval in PROC and implications for Rina-S? - Management acknowledged the approval as a good option for patients but believes Rina-S can be more transformative for a broader population [62][64] Question: Confirmation on interim results for Epkinly frontline DLBCL trial? - Management reiterated that the readout for the study is expected to happen in 2026 [55][68]

Genmab (NasdaqGS:GMAB) Q4 2025 Earnings call February 17, 2026 12:00 PM ET Company ParticipantsAnthony Pagano - CFOBenjamin Jackson - VP of Equity ResearchBrad Bailey - CCOJames Gordon - Director and Head of European Pharma and Biotech & Life Sciences Equity ResearchJan van de Winkel - CEOJudith Klimovsky - Chief Development OfficerMatthew Phipps - Group Head–BiotechnologyTahamtan Ahmadi - CMOVictor Floc'h - Equity Research of PharmaceuticalsXian Deng - Executive Director and Pharma and Biotech Equity Resea ...

Financial Data and Key Metrics Changes - Total revenue increased by 19% to $3.7 billion in 2025, driven by strong execution across the royalty portfolio and commercialized medicines [24][25] - Operating profit expanded to $1.26 billion, reflecting strong execution and increasing operating leverage as the business scales [25][27] - Sales of proprietary medicines totaled $632 million, up 54% year over year, accounting for approximately 28% of total revenue growth [14][24] Business Line Data and Key Metrics Changes - Epkinly achieved $468 million in sales for the year, representing a 67% year-over-year increase, driven by its dual indication in diffuse large B-cell lymphoma and follicular lymphoma [15][24] - Tivdak generated $164 million in sales, representing a 26% year-over-year increase, maintaining market leadership in recurrent or metastatic cervical cancer [19][20] Market Data and Key Metrics Changes - Epkinly closed 2025 with regulatory approvals in more than 65 countries, nearly all featuring the dual indication [15] - The U.S. market saw increased uptake for Epkinly, particularly following its approval in second-line follicular lymphoma [17][18] - Tivdak's launch in Germany showed strong uptake, with positive physician feedback [20] Company Strategy and Development Direction - The company aims to accelerate the development of its late-stage pipeline and maximize the potential of its commercialized medicines [5][24] - The acquisition of Merus is expected to enhance the late-stage portfolio with petosemtamab, contributing to sustainable growth [6][25] - The focus for 2026 includes advancing proprietary portfolio impact, expanding market footprint, and preparing for multiple product launches [22][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to execute on key data readouts in 2026 and subsequent high-impact launches in 2027 [29] - The company anticipates continued revenue growth driven by Epkinly and its royalty portfolio, with a guidance of 14% total revenue growth for 2026 [26][28] - Management highlighted the importance of maintaining substantial profitability while investing in growth opportunities [27][28] Other Important Information - The company has five combined breakthrough therapy designations for its late-stage programs, indicating multi-billion dollar potential [7] - The anticipated data readouts in 2026 are expected to set the stage for multiple important product launches and line extensions in 2027 [8][10] Q&A Session Summary Question: Next steps for Epkinly following EPCORE DLBCL-1 study results - Management confirmed that the study showed positive progression-free survival but missed overall survival, with ongoing discussions with regulatory agencies about the data [31][33] Question: Update on outpatient data for Epkinly - Management indicated that the outpatient study is crucial for modifying the label and facilitating administration in the community [40][42] Question: Expectations for Rina-S pivotal phase two readout - Management stated that the study is designed to support accelerated approval based on overall response rate and duration of response [47][49] Question: Expectations for EPCORE DLBCL-4 trial outcomes - Management expressed optimism that the trial will lead to registration in second-line and third-line settings, differentiating it from other studies [53][55] Question: Thoughts on pembro approval in PROC and implications for Rina-S - Management acknowledged the approval as a good option for patients but believes Rina-S can be more transformative for a broader population [57][59] Question: Clarification on phase 3 for petosemtamab - Management confirmed that the phase 3 studies have dual endpoints of overall response rate and overall survival, which are standard in areas of unmet medical need [75]

Summary of Wheaton Precious Metals Conference Call Company Overview - **Company**: Wheaton Precious Metals (NYSE: WPM) - **Event**: Silver Stream Transaction conference call regarding Antamina mine - **Date**: February 17, 2026 Key Points Industry and Company Context - Wheaton Precious Metals is positioned as the largest precious metal streaming company globally, with a focus on silver production [3][4] - The company has acquired an additional silver stream on the Antamina mine in Peru, partnering with BHP [3][4] Acquisition Details - **Transaction Value**: $4.3 billion for 33.75% of the silver produced at Antamina, marking the largest precious metal stream ever executed [3][4][8] - **Payment Structure**: Upfront payment of $4.3 billion and ongoing payments equal to 20% of the spot silver price [8][19] - **Production Forecast**: Attributable silver production is expected to average approximately 6 million ounces per year for the first five years and 5.4 million ounces per year for the first ten years [9] Production Guidance and Growth - Updated production guidance indicates a 50% growth by 2030, targeting 1.2 million gold equivalent ounces annually [4][17] - Antamina is projected to contribute approximately 18% of Wheaton's total production by 2030, solidifying its position as the second-largest asset in the portfolio [9][11] Asset Quality and Longevity - Antamina is recognized as a long-life, low-cost operation, contributing to immediate production and cash flow [5][11] - The mine has a proven track record of extending its life through resource conversion and exploration, with a current mine life extended to 2036 [12][63] - The asset is expected to operate for decades, with significant exploration potential and ongoing investments in infrastructure [12][36] Financial Position and Strategy - Wheaton plans to fund the acquisition through a combination of existing liquidity, free cash flows, and a new $1.5 billion term loan [19] - The company anticipates generating over $10 billion in operating cash flow through 2028 at current spot prices, with a return to a net cash position expected within a year [19][98] - The transaction represents only 6.5% of Wheaton's total market capitalization, indicating strong strategic fit and accretion potential [19] Community and Sustainability Commitment - Wheaton emphasizes its commitment to supporting local communities and sustainability practices, particularly in Peru [10] Market Outlook - The silver market is expected to remain in a supply deficit for the next five years, with increasing investment demand [58] - Wheaton's management expresses confidence in the long-term fundamentals of silver, despite recent price fluctuations [58] Risk Management - The acquisition reduces concentration risk, as Antamina will represent under 18% of Wheaton's total assets, while Salobo will be under 25% in the coming years [39][40] - The company maintains a strong credit position with 70% of its exposure to investment-grade mining partners, significantly decreasing credit risk [11] Future Opportunities - Wheaton is exploring additional opportunities for growth, particularly in the copper space, which is expected to require significant capital investment [82] Additional Insights - The transaction with BHP is seen as a validation of the streaming model, highlighting its attractiveness as a source of capital for major mining companies [84] - The company is actively engaging with other large miners for potential future streaming agreements [82]